Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancer
New Podcast
Skip to content
FOR INVESTORS
News and Events
Corporate Presentation
Stock Information
Shareholder Services
SEC Filings
Corporate Governance
Onvansertib
Pipeline
Clinical Programs
mCRC
mCRPC
mPDAC
Leadership
Management Team
Board of Directors
Scientific Advisory Board
Contact Us
For Investors
News and Events
Corporate Presentation
Stock Information
Shareholder Services
SEC Filings
Corporate Governance
Investor Relations
Press Releases
Events
Press Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Get News Alerts by Email
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Video
Audio
Photos
Documents
Events
Standard
Sep 26, 2023
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy
Sep 5, 2023
Cardiff Oncology to Present at Upcoming Investor Conferences in September
Aug 9, 2023
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
Aug 7, 2023
Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship
Jul 24, 2023
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 20, 2023
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 5, 2023
Cardiff Oncology to Present at the Jefferies Healthcare Conference
May 4, 2023
Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update
Mar 28, 2023
Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer
Mar 6, 2023
Cardiff Oncology Formally Introduces Scientific Advisory Board
Mar 2, 2023
Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
Feb 27, 2023
Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference
Feb 2, 2023
Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer
Photos
1
Jan 10, 2023
Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference
Nov 21, 2022
Cardiff Oncology to Present at Upcoming Investor Conferences
Nov 8, 2022
Cardiff Oncology to Present at the Jefferies London Healthcare Conference
Nov 3, 2022
Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates
Sep 12, 2022
Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates
Sep 10, 2022
Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022
Sep 8, 2022
Cardiff Oncology to Present at Upcoming Investor Conferences in September
Sep 6, 2022
Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022
Aug 29, 2022
Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022
Aug 4, 2022
Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates
Jul 5, 2022
Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022
May 17, 2022
Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
16
»